◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Mirtazapine

Extensively Studied

Tetracyclic NaSSA developed by Organon in the 1990s — α2 antagonist + 5-HT2A/2C/3 antagonist + potent H1 antagonist.

Aliases (6)
Remeron · Remeron SolTab · Avanza · Zispin · Org-3770 · 6-Aza-mianserin
TYPICAL DOSE
15 mg PO at bedtime as starter dose
Pre-bed
ROUTE
Oral (tablet)
Oral
CYCLE
None. Designed for steady-state daily use
As prescribed
STORAGE
Room temp; original container
Room temp

Overview

What is Mirtazapine?

Mirtazapine (Remeron) is a tetracyclic noradrenergic and specific serotonergic antidepressant (NaSSA). It is FDA-approved for major depressive disorder and used off-label for insomnia, appetite, and anxiety.

Key Benefits

Effective for depression with prominent insomnia and weight loss, sedating and appetite-stimulating at low doses, antiemetic, anxiolytic, and lacks sexual side effects common to SSRIs.

Mechanism of Action

Antagonizes presynaptic α2-adrenergic autoreceptors and heteroreceptors, increasing norepinephrine and serotonin release. Also blocks postsynaptic 5-HT2A, 5-HT2C, 5-HT3, and H1 histamine receptors, accounting for sedation, appetite gain, and antiemetic effects.

Pharmacokinetics

—·—
PeakHalf-life
Approximate curve — visual aid only, not data-precise PK
▸Brand options5 known
RemeronRemeron SolTabAvanzaZispinOrg-3770

StatusRx (US, EU, UK, AU, CA, IN — globally available); NOT controlled. Generic since ~2004.

Research Indications

Most Effective

Mirtazapine is one of the most potent H1 inverse agonists in clinical use

Ki ~0.14 nM, comparable to or exceeding diphenhydramine (Benadryl) and doxepin. A single 15 mg dose produces >80% H1 receptor occupancy.

Research Protocols

Disclaimer: These are commonly discussed research protocols and not medical advice.

Goal:3.75 mg, 7.5 mg, or 15 mg
Dose:7.5 mg tablets are not commercially produced in US — requires splitting 15 mg tablets or compounded 7
Frequency:—
Solo:—
Cycle:—
Goal:Do not ignore weight + waist trajectory
Dose:—
Frequency:—
Solo:—
Cycle:—

Peptide Interactions

L-tryptophan (substrate)
Synergistic

feeds the upstream serotonin pool that mirtazapine then disinhibits + funnels through 5-HT1A. Theoretically synergistic for mood + sleep. Not formally needed…

CBT for insomnia / depression
Synergistic

behavioral component matters; mirtazapine alone often used as bridge to CBT response.

California Rocket Fuel (mirtazapine + venlafaxine)
Synergistic

Stahl-coined combination. Mirtazapine α2 + 5-HT2/3 antagonism complements venlafaxine's SNRI mechanism + cancels venlafaxine's GI/sexual side effects via 5-H…

MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline at high doses)
Avoid

serotonin syndrome risk. Selegiline 1-2.5 mg/day (in the user's V stack+ plan) is MAO-B selective so theoretical risk is low, but combination not formally st…

Other strong serotonergic agents
Avoid

(SSRIs at full doses, SNRIs, tramadol, MDMA, dextromethorphan, tianeptine at high doses) — additive serotonergic risk

Other CNS depressants
Avoid

(alcohol, benzos, Z-drugs, opioids, gabapentinoids, phenibut, GHB, DORAs like daridorexant) — additive sedation + respiratory depression at high combined load

Strong CYP3A4 inducers
Avoid

(carbamazepine, phenytoin, rifampin, St. John's wort) — reduce mirtazapine exposure, may lose efficacy

Strong CYP1A2/2D6/3A4 inhibitors
Avoid

(fluvoxamine, ketoconazole, ciprofloxacin) — increase mirtazapine exposure, intensify side effects

Bromantane
Avoid

(in V5 plan) — same-evening combination contradictory: bromantane upregulates DA synthesis (wake/motivation), mirtazapine sedates. AM bromantane + PM mirtaza…

Modafinil
Avoid

same-day combination has been used (modafinil AM, mirtazapine PM) as "California Rocket Fuel for sleep + wake" but this is not a relevant-to-archetype patter…

All V4 stack components
Compatible

(DHA, magtein, citicoline, NAC, PS, magnesium glycinate, curcumin phytosome, rhodiola, theanine, D3+K2, beta-alanine, vitamin C) — no significant PK or PD in…

Caffeine
Compatible

CYP1A2 substrate, mild interaction direction is opposing (caffeine doesn't meaningfully induce CYP1A2 at consumed doses); no clinical concern

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

!

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

  • Day 1
    PK-driven acute peak per administration. Verify dose tolerated.
  • Week 1
    Steady-state reached for most daily-dosed pharma.
  • Week 2-4
    Therapeutic effect established; titration window if needed.
  • Long-term
    Periodic monitoring per drug class (labs, BP, ECG as applicable).

Side Effects & Safety 14

Side Effects

  1. 1Somnolence / sedation — ~50%+ at any dose. The defining feature.
  2. 2Weight gain — ~20-40% gain ≥7 lb in first 3-6 months. Median gain ~2-10 lb.
  3. 3Increased appetite — near-universal first weeks; carb-craving signature
  4. 4Dry mouth — ~25%
  5. 5Dizziness — ~7-10%, mostly first weeks; orthostatic component
  6. 6Constipation — ~13%
  7. 7Asthenia / fatigue — ~8-10%
  8. 8Dreams (abnormal / vivid) — ~4-6%
  9. 9Confusion — ~2-3%
  10. 10Tremor — ~2%
  11. 11Peripheral edema — ~2-5%
  12. 12Restless legs syndrome (RLS) — ~8-28% in some studies (Mayo, multiple case series). This is a SIGNIFICANTLY HIGHER incidence than most antidepressants and is a real disqualifier for athletes whose legs already do meaningful daily work. Often appears within days of starting.
  13. 13Hypercholesterolemia / triglyceridemia — well-documented metabolic side effect, partially weight-gain-independent (Heinz et al. 2023, Naunyn-Schmiedeberg)
  14. 14Morning hangover / grogginess — variable, sometimes persistent

When to Stop

  • Agranulocytosis / severe neutropenia (ANC <0.5 × 10⁹/L) — ~11 per 10,000 patients exposed, typically 9-61 days after initiation. 6 cases of agranulocytosis in ~2 million exposures reported. Resolves on discontinuation. Manufacturer label requires discontinuation if patient develops sore throat, fever, stomatitis, or other infection signs along with low WBC. Some clinicians monitor CBC several times in first year.
  • Stevens-Johnson syndrome / TEN — extremely rare reports
  • Hepatotoxicity — uncommon; transaminase elevations occasional
  • Suicidal ideation — class-wide antidepressant FDA warning, small absolute increase in <25yo (a user in this archetype is 20)
  • Manic switch — described in undiagnosed bipolar
  • Serotonin syndrome — when stacked with MAOIs, other serotonergic agents
  • Sleep paralysis / parasomnias — uncommon
  • First 8 weeks: weight + appetite + sedation peak; RLS onset window; suicidal ideation watch (<25yo)
  • First 6 months: weight + lipid trajectory; agranulocytosis cases mostly cluster in first 2 months but extend to 8 months in case reports
  • Any dose increase: may transiently worsen sedation, but counterintuitively may IMPROVE sedation if going from 15 → 30+ mg (low-dose paradox)

References

Mirtazapine - StatPearls (NCBI Bookshelf)

ncbi.nlm.nih.gov

definitive overview, mechanism, dosing, side effects

View Study

Mirtazapine - Wikipedia

en.wikipedia.org

broad reference, regulatory history, low-dose paradox documentation

View Study

Mirtazapine Essentials: MOA, Indications, Adverse Effects, Pharmacokinetics and Dosing (Psychopharmacology Institute)

psychopharmacologyinstitute.com

clinician-facing summary, NaSSA mechanism

View Study

Mirtazapine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects (Psychopharmacology Institute)

psychopharmacologyinstitute.com

comprehensive prescribing reference

View Study

Cipriani et al. 2018 — Comparative Efficacy and Acceptability of 21 Antidepressants (Lancet)

thelancet.com · 2018

32802-7/fulltext) — network meta-analysis ranking mirtazapine in top efficacy tier

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Mirtazapine
Daridorexant
WATCH-LIST
Dual Orexin Receptor Antagonist (DORA) — sleep medication
HIGH
Bupropion
OPTIONAL-ADD
NDRI (norepinephrine + dopamine reuptake inhibitor) + nicotinic α4β2 antagonist (atypical antidepressant)
MEDIUM
L-Tryptophan
STRONG-CANDIDATE
Essential amino acid; serotonin/melatonin precursor
HIGH

More in Pharmaceutical · Oral

94 compounds in bucket
3-n-Butylphthalide (NBP)
OPTIONAL-ADD
Plant-derived multi-target neuroprotectant (phthalide; originally isolated from celery seed Apium graveolens); approved Chinese pharmaceutical for acute ischemic stroke
LOW
5-Amino-1MQ
WATCH-LIST
NNMT inhibitor (nicotinamide N-methyltransferase inhibitor) — small-molecule oral; methylation/NAD-sparing metabolic modulator
LOW
9-Methyl-β-carboline
WATCH-LIST
β-carboline alkaloid (tricyclic pyridoindole) — multimodal dopaminergic neurorestorative + dual MAO-A/B inhibitor + neurotrophic-factor inducer
LOW
ACD-856
WATCH-LIST
Pan-Trk receptor positive allosteric modulator (Trk-PAM) — small-molecule triazinetrione
HIGH
Adderall
SKIP-FOR-NOW
Amphetamine — substituted phenethylamine releasing agent (SNDRA)
MEDIUM
Adrafinil
SKIP-PERMANENT
Eugeroic — modafinil prodrug
HIGH